Is Journal of Clinical Oncology Indexed in PubMed? Yes, and MEDLINE Is Active from Launch
Journal of Clinical Oncology is indexed in PubMed and currently indexed for MEDLINE from volume 1, issue 1, which makes its indexing record unusually clean.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Journal of Clinical Oncology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 41.9 puts Journal of Clinical Oncology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~15% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: Journal of Clinical Oncology takes ~~30 days. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: yes. **Journal of Clinical Oncology is indexed in PubMed and currently indexed for MEDLINE, with both coverage lines beginning at volume 1, issue 1 in 1983.
** That matters because JCO is a flagship clinical-oncology journal whose papers need to move quickly into trial interpretation, guideline work, and day-to-day oncology search workflows.
Direct answer
If you publish in Journal of Clinical Oncology, your paper is discoverable in PubMed and the journal remains actively indexed for MEDLINE.
NLM field | What the record shows | Why it matters |
|---|---|---|
publication start year | 1983 | the title's current identity begins with its indexed history |
PubMed coverage | v1n1, 1983- | searchable coverage begins from launch |
MEDLINE coverage | v1n1, 1983- | active curated indexing also begins from launch |
current indexing status | Currently indexed for MEDLINE | the title remains fully active in NLM indexing |
current subset | Index Medicus | the journal sits inside the established biomedical index |
That is the clean discoverability answer. JCO does not have a messy launch-to-indexing gap under the current title.
Why this matters for JCO
Strong JCO papers often need to reach:
- practicing oncologists
- cooperative-group and investigator-initiated trial teams
- guideline and consensus writers
- disease-focused specialists outside one narrow lane
- translational oncology readers interpreting clinical consequence
Those readers do not only browse the journal brand. They search by disease, regimen, end point, biomarker, survival question, or treatment sequencing issue. PubMed indexing is how a JCO paper enters that real search behavior.
That is why the indexing record matters even for a famous society journal. Reputation helps. Search visibility is what makes the paper operationally usable.
What the indexing record tells you in practice
Practical question | What the record tells you |
|---|---|
will a published paper be visible in standard oncology literature searches? | yes |
is the title actively indexed for MEDLINE? | yes |
is there any current-title launch gap to worry about? | no |
does this prove the manuscript belongs in JCO? | no |
Again, the last line is the important limit.
PubMed versus MEDLINE for JCO
For JCO, the distinction is straightforward but still worth naming.
- PubMed means the paper is searchable in the main biomedical database oncology teams use.
- MEDLINE means the title is actively curated inside the NLM journal index.
Because both lines start at volume 1, the indexing answer is clean. That matters for a journal that often publishes trial-defining or practice-shaping material. There is no ambiguity about whether the title sits fully inside the biomedical search system.
How this compares with nearby oncology journals
Journal pattern | What the indexing answer usually helps confirm | What it does not settle |
|---|---|---|
flagship clinical-oncology title like JCO | broad search visibility across oncology practice and trial reading | whether the manuscript has JCO-level consequence |
disease-specific oncology journal | strong relevance inside one disease lane | whether the work should reach broader oncology readers |
lower-tier or newer title | current visibility may still be developing | whether the manuscript is strong enough for a flagship |
This is why a strong PubMed answer is useful but still not the submission decision.
How to verify the record yourself
The direct check is easy:
- open the NLM Catalog record
- confirm the PubMed line
- confirm the MEDLINE line
- check Current Indexing Status
- run a direct journal search in PubMed
For JCO, that manual check is unusually simple because the record begins cleanly at launch. That is part of what makes the answer more robust than a generic "yes, it's in PubMed."
What we see in PubMed-Indexing Questions for JCO
For PubMed-indexing questions for Journal of Clinical Oncology, three patterns come up often.
The society-journal assumption. Some authors assume that because JCO is a major ASCO journal, they do not need to verify the indexing details. Usually that assumption is correct, but the NLM record still gives the cleaner proof and confirms the launch-to-indexing continuity.
The indexing-equals-fit shortcut. We also see teams use strong indexing as reassurance that the paper should go to JCO. That is not the right leap. The database answer is yes. The editorial answer still depends on breadth, consequence, and audience.
The prestige-over-search-logic mistake. Another pattern is focusing on JCO's brand and forgetting that search behavior is what actually makes a published paper useful. PubMed and MEDLINE status are part of how the paper becomes visible to clinicians, trialists, and review authors in practice.
That is the useful gain on this page. The indexing record is strong. The journal-fit decision is still separate.
What indexing does and does not tell you
This page answers the discoverability question. It does not tell you:
- whether the manuscript has enough broad oncology consequence for JCO
- whether the paper is better framed for Blood or a narrower oncology title
- whether the current draft is ready for a flagship clinical-oncology audience
That is why the more useful next pages are:
If the fit question is what you actually need answered, a Journal of Clinical Oncology submission readiness check gives you a manuscript-specific signal before you submit.
What the NLM record means in practice for authors
For JCO, the indexing record is not where the uncertainty usually sits. The title has a clean launch-to-indexing history, active MEDLINE coverage, and the kind of database visibility you would expect from a flagship oncology journal.
That matters because some teams still spend time checking discoverability when the real risk is editorial selectivity. If JCO rejects a paper, it is rarely because the journal lacks search visibility. It is because the manuscript may not have enough consequence, breadth, or practice-changing value for the audience.
The indexing record is still worth checking because it lets you answer the discoverability question with evidence rather than reputation. It also helps when you are comparing JCO against neighbors like Blood or a narrower oncology title. Search coverage is not the differentiator there. Audience and editorial bar are.
So the practical use of this page is simple: use it to clear the database-status question quickly, then move the decision back to manuscript strength, journal fit, and competitive positioning.
Why clean launch-to-index continuity matters for JCO
This record is stronger than a generic yes because both the PubMed and MEDLINE lines begin at volume 1 in 1983. That means authors do not have to interpret a delayed-indexing story or wonder whether the title's first years sit outside the normal oncology search system.
For a journal that often publishes trial-defining or guideline-relevant work, that clean continuity matters. It supports the expectation that accepted papers move quickly into practice-facing literature use rather than only into brand-driven journal reading.
Submit If / Think Twice If
Use this indexing answer as enough reassurance if:
- your main concern is whether a published paper will be easy to find in oncology searches
- you want confirmation that the journal is actively inside both PubMed and MEDLINE
- you value a clean launch-to-indexing record
Think twice if:
- you are using indexing as a shortcut for JCO fit
- the manuscript may still be too narrow or too weak for a flagship clinical-oncology audience
- what you really need is a submission-bar or audience decision instead
If the fit question is what you actually need answered, a Journal of Clinical Oncology submission readiness check gives you a manuscript-specific signal before you submit.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
Practical verdict
Yes, Journal of Clinical Oncology is indexed in PubMed and currently indexed for MEDLINE, and both lines begin from volume 1 in 1983. That is a clean, high-confidence indexing answer.
If your question is whether a published paper will be visible in the main oncology search workflow, the answer is yes. If your real question is whether the manuscript deserves a JCO readership, that remains a separate editorial-fit judgment.
Or see example reports before you finalize.
Frequently asked questions
Yes. Journal of Clinical Oncology is indexed in PubMed and currently indexed for MEDLINE according to the NLM Catalog.
Yes. The NLM Catalog shows PubMed and MEDLINE coverage from volume 1, issue 1 in 1983.
No. The NLM record shows Index Medicus, but not the AIM core clinical journals subset.
Open the journal’s NLM Catalog record, check the PubMed and MEDLINE lines plus Current Indexing Status, then confirm recent papers appear normally in PubMed.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
- Journal of Clinical Oncology Submission Guide: Editorial Screening Guide
- How to Avoid Desk Rejection at Journal of Clinical Oncology
- Is Journal of Clinical Oncology a Good Journal? The ASCO Flagship for Practice-Changing Oncology
- Journal of Clinical Oncology Submission Process: What Happens From Upload to First Decision
- Journal of Clinical Oncology Under Review: What the Status Means
- Journal of Clinical Oncology Review Time: What Authors Can Actually Expect
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.